Modified mrna for multicell transformation
AssigneeTuhura Biosciences, Inc.
InventorsMICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
Life of this patent
Estimating the term…
Abstract
Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.
Claims13
A human codon optimized nucleic acid selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 18 and SEQ ID NO:
- 19, wherein the nucleic acid will express an immunogenic polypeptide when transfected into mammalian cancer cells.
A method of preparing a cancer cell vaccine comprising using a nucleic acid selected from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 18 and SEQ ID NO:
- 19 to transfect human cancer cells in vitro to express an immunogenic polypeptide.
A method of forming a cancer cell vaccine in vivo comprising:
- selecting a nucleic acid from the group consisting of SEQ ID NO:
- 17, SEQ ID NO:
- 18 and SEQ ID NO:
- 19;
- and
- transfecting solid tumor cells in a cancer patient with the nucleic acid, wherein the polypeptide expressed in the tumor cells produces an immune response.
Dependencies are inferred from the claim text.